| Literature DB >> 3995377 |
H I Scher, T Ahmed, A Yagoda, A P Kyriazis, R C Watson.
Abstract
A phase II trial with bisantrene was performed simultaneously against urothelial tumors in nude mice and in patients with metastatic transitional cell carcinoma. The starting dose was 260 mg/m2, intravenously, every 3 weeks. No responses were seen in the in vivo animal study or in 13 treated patients.Entities:
Mesh：
Substances：
Year: 1985 PMID： 3995377 DOI： 10.3109/07357908509017495
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176